# ABC-X (NCT03340129)

> Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab plus stereotactic radiotherapy
- Indication: melanoma brain metastases

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03340129
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Melanoma Institute Australia
- Conditions: Melanoma Stage Iv
- Interventions: Ipilimumab; Nivolumab; Stereotactic Radiotherapy; Salvage therapy
- Enrollment: 218
- Primary outcome: Neurological specific cause of death

## Indexed commentary on ABC-X so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4
- YouTube: 2
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=abc-x-nct03340129

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03340129", "email": "<work email>"}; the inbox owner confirms by the emailed link.